Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Atopic Dermatitis

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Br J Dermatol

Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C, UK-Irish A-STAR Study Group

doi: 10.1093/bjd/ljae287

Further Publications Immunology

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real-world data from a multicentre study

J Eur Acad Dermatol Venereol

Nikolaou V, Panou E, Tsimpidakis A, Koumprentziotis IA, Patsatsi A, Siakantaris M, Kruger-Krasagakis SE, Marinos L, Georgiou E, Lampadaki K, Velissari A, Daponte AI, Doxastaki A, Kaliampou S, Vaiopoulos A, Konstandinou I, Koumourtzis M, Lakiotaki E, Pappa V, Tsamaldoupis A, Stratigos A, Papadavid E

doi: 10.1111/jdv.20350

Atopic Dermatitis

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

J Am Acad Dermatol

Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA

doi: 10.1016/j.jaad.2024.04.026

Atopic Dermatitis

Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study

J Dermatolog Treat

Darbellay B, Huber M, Bisschoff IJ, Guillod C, Hügel R, Pirkhammer D, Sator PG, Taskesen T, Lang CCV

doi: 10.1080/09546634.2024.2415407

Psoriasis

Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study

J Eur Acad Dermatol Venereol

Gerdes S, Ostendorf R, Süß A, Schadeck T, Taut F, Makuc J, Scharfenberger L, Jacobsen S, Trenkler N, Behrens J, Joks G, Tabori S, Mortazawi D

doi: 10.1111/jdv.19927

Atopic Dermatitis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)

Br J Dermatol

Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K

doi: 10.1093/bjd/ljae404

Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

J Am Acad Dermatol

Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR

doi: 10.1016/j.jaad.2024.09.039

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials

Lancet

Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C, ARCADIA 1 and ARCADIA 2 Study Investigators

doi: 10.1016/S0140-6736(24)01203-0

Related content

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real-world data from a multicentre study

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study

Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials